Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion

  • Authors:
    • Yuta Sato
    • Shin‑Ei Kudo
    • Katsuro Ichimasa
    • Shingo Matsudaira
    • Yuta Kouyama
    • Kazuki Kato
    • Toshiyuki Baba
    • Kunihiko Wakamura
    • Takemasa Hayashi
    • Toyoki Kudo
    • Noriyuki Ogata
    • Yuichi Mori
    • Masashi Misawa
    • Naoya Toyoshima
    • Tomoyuki Ishigaki
    • Yusuke Yagawa
    • Hiroki Nakamura
    • Tatsuya Sakurai
    • Yukiko Shakuo
    • Kenichi Suzuki
    • Yui Kudo
    • Shigeharu Hamatani
    • Fumio Ishida
    • Hideyuki Miyachi
  • View Affiliations

  • Published online on: September 28, 2018     https://doi.org/10.3892/ol.2018.9527
  • Pages: 7264-7270
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

With recent advances in endoscopic treatment, many T1 colorectal carcinomas (CRCs) are resected endoscopically with a negative margin. However, some lesions exhibit skip lymphovascular invasion (SLVI), which is defined as the discontinuous foci of the tumor cells within the colon wall. The aim of the present study was to reveal the clinicopathological features of T1 CRCs with SLVI and validate the Japanese guidelines regarding SLVI. A total of 741 patients with T1 CRCs that were resected surgically between April 2001 and October 2016 in our hospital were divided into two groups: With SLVI and without SLVI. Clinicopathological features compared between the two groups were patient's gender, age, tumor size, location, morphology, lymphovascular invasion, tumor differentiation, tumor budding and lymph node metastasis. The incidence of T1 CRCs with SLVI was 0.9% (7/741). All cases with SLVI were found in the sigmoid colon or rectum. T1 CRCs with SLVI showed significantly higher rates of lymphovascular invasion than those without SLVI (P<0.01). In conclusion, lymphovascular invasion was a significant risk factor for SLVI in T1 CRCs, and for which surgical colectomy was necessary. The Japanese guidelines are appropriate regarding SLVI. Registered in the University Hospital Medical Network Clinical Trials Registry (UMIN000027097).

Introduction

The incidence and mortality of colorectal carcinoma (CRC) have been increasing in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men (1,2). Advanced methods of endoscopic treatment have been developed during recent decades, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) (38). Therefore, many T1 CRCs are resected endoscopically. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines for treatment of colorectal cancer indicate that the curative criteria for T1 CRCs after endoscopic resection are negative vertical margin, well/moderately differentiated tubular or papillary carcinoma, no vessel invasion, a submucosal invasion depth of less than 1,000 µm, and budding grade 1 because of the very low risk of lymph node metastasis (LNM) (1). When a lesion meets these criteria, endoscopic resection is considered to be an adequate cure, while additional surgery with lymph node dissection is recommended when these criteria are not met.

Recently, a Japanese study reported that there were some cases in T1 CRCs with ‘skip lymphovascular invasion’ (SLVI), which is defined as the discontinuous foci of the tumor cells within the colon wall (9). Lesions with SLVI cannot be diagnosed with specimens that have been endoscopically resected. However, lesions with SLVI require surgical colectomy to prevent recurrence or metastasis. Although detecting and managing such lesions are critical, the clinicopathological features of these lesions have not been fully elucidated. Because the number of colorectal ESD is increasing recently, these are urgent matters that need to be resolved. The aim of the present study was to reveal the incidence and the clinicopathological features of T1 CRCs with SLVI, and to validate the JSCCR guidelines regarding SLVI.

Materials and methods

Study patients

A total of 789 patients with T1 CRC surgically resected between April 2001 and October 2016 at Showa University Northern Yokohama Hospital, Japan, were recruited. Patients who were diagnosed with familial adenomatous polyposis, Lynch syndrome, ulcerative colitis, and those who had synchronous invasive carcinoma or chemotherapy were excluded. Those who were unable to obtain clinicopathological features were also excluded. Initial or additional surgeries after endoscopic resection with lymph node dissection were performed based on the JSCCR guidelines. Patients were divided into two groups, with SLVI and without SLVI (Fig. 1). SLVI is a form of lymphovascular invasion or carcinoma within the colon wall, which is consistent with Okamoto et al (9) (Figs. 2 and 3). The following clinicopathological features were analyzed and compared between the two groups: Patient's gender, age, tumor size, location, morphology, lymphovascular invasion, tumor differentiation, tumor budding and the presence of LNM.

In a substudy, 560 patients with T2 CRCs resected surgically in our hospital between April 2001 and October 2016 were divided into two groups, with SLVI and without SLVI, and compared (Fig. 4). Features analyzed were patient's gender, age, tumor size, location, lymphovascular invasion, tumor differentiation and the presence of LNM.

Assessment of clinicopathological factors

Patients' gender, age, tumor size, location and morphology were reviewed from the electronic records system. Endoscopic morphology was classified as a depressed, flat, or protruded type according to Kudo's morphological classification (10).

All resected lesions were retrieved and immediately fixed in a 10% buffered formalin solution for 24–48 h. Each species was cut into 2- or 3-mm-wide longitudinal slices. The tissues were examined by one pathologist (SH) based on the World Health Organization criteria and the JSCCR guidelines, and assessed using hematoxylin and eosin (H&E) staining (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) (1,11). In addition, lymphovascular invasion was evaluated using Victoria blue (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) or immunostaining with D2-40 (Dako; Agilent Technologies, Inc.). Histological grade was based on dominant differentiated tumor component and was classified according to World Health Organization criteria (11).

Statistical analysis

All statistical analyses were performed by using ‘EZR’ (Easy R) v.1.37 for Windows (12). Independent Student's t-tests were used to compare the groups of continuous, normally distributed variables. Fisher's exact test was used to determine the significance of differences between groups for dichotomous variables. All statistical tests were two-tailed, and P<0.05 was considered to indicate a statistically significant difference.

Ethical considerations

This study was approved by the Institutional Review Board of Showa Northern Yokohama Hospital (no. 1508-03), and was registered in the University Hospital Medical Network Clinical Trials Registry (UMIN000027097). Written informed consent was obtained from all patients before endoscopy.

Results

Patients' characteristics

A total of 741 T1 CRC patients were included in this study, 469 (63%) were men and 272 (37%) were women. The mean age was 65 years old (range 31–94). The mean tumor size was 21 mm (range 10–120). In total, 515 cases (69%) were located in the sigmoid colon or rectum, and 226 (31%) were located in other sites. Regarding morphology, 220 cases (29%) were diagnosed as depressed type and 521 cases (71%) were non-depressed type. Lymphovascular invasion appeared in 356 cases (48%). A total of 4 cases (0.5%) were poorly differentiated adenocarcinoma or mucinous adenocarcinoma (por/muc). LNM was found in 84 cases (11%). The incidence of T1 CRCs with SLVI was 0.9% (7/741).

A total of 501 patients with T2 CRCs were included, 253 (51%) of whom were men and 248 (49%) were women. The mean age was 66 years old (range 28–91). The mean tumor size was 31 mm (range 8–117). There were 357 cases located in the sigmoid colon or rectum. Lymphovascular invasion appeared in 348 cases (70%). LNM was found in 136 cases (27%). The incidence of T2 CRCs with SLVI was 1.6% (8/501).

Comparisons of pathological features between the patients with and without SLVI

The comparisons of clinicopathological features between patients with and without SLVI in T1 CRCs are shown in Table I. All T1 CRCs with SLVI showed lymphovascular invasion. In addition, cases with SLVI also showed a higher rate of lymphovascular invasion (P<0.01) and depressed type (P=0.03) than cases without SLVI. Although all cases with SLVI were in the sigmoid or rectum, there were no significant differences between occurrence at either site (P=0.11). There were no significant differences in other clinicopathological features between the two groups.

Table I.

Comparison of clinicopathological features between patients with and without skip lymphovascular invasion in T1 colorectal carcinomas.

Table I.

Comparison of clinicopathological features between patients with and without skip lymphovascular invasion in T1 colorectal carcinomas.

CharacteristicsWith SLVI (n=7)Without SLVI (n=734)P-value
Sex 0.96
  Male5464
  Female2270
Age, years (range)68 (42–79)65 (31–94)0.30
Tumor size, mm (range)20 (13–33)21 (10–120)0.44
Location 0.11
  Sigmoid or rectum7508
  Other site0226
Morphology 0.03
  Depressed5215
  Non-depressed2519
Lymphovascular invasion <0.01
  Positive7349
  Negative0385
Tumor differentiation 0.84
  Por or Muc04
  Well or Mod or Pap7730
Tumor budding 0.11
  Positive2472
  Negative5262
Lymph node metastasis 0.18
  Positive282
  Negative5652

[i] SLVI, skip lymphovascular invasion; CRC, colorectal carcinoma; Por, poorly differentiated adenocarcinoma; Muc, mucinous carcinoma; Well, well differentiated adenocarcinoma; Mod, Moderately poorly differentiated adenocarcinoma; Pap, papillary adenocarcinoma.

The comparisons of clinicopathological factors between cases with SLVI and cases without SLVI in T2 CRCs are shown in Table II. All T2 CRCs with SLVI were also in the sigmoid colon or rectum (P=0.11) and showed lymphovascular invasion (P=0.11). There were also no significant differences in other clinicopathological features.

Table II.

Comparison of clinicopathological features between patients with and without skip lymphovascular invasion in T2 colorectal carcinomas.

Table II.

Comparison of clinicopathological features between patients with and without skip lymphovascular invasion in T2 colorectal carcinomas.

CharacteristicsWith SLVI (n=8)Without SLVI (n=493)P-value
Sex 0.29
  Male6247
  Female2246
Age, years (range)61 (44–84)67 (28–91)0.41
Tumor size, mm (range)  23 (10–37)31 (8–117)0.15
Location 0.11
  Sigmoid or rectum8349
  Other site0144
Lymphovascular invasion 0.11
  Positive8348
  Negative0145
Tumor differentiation 0.59
  Por or Muc015
  Well or Mod or Pap8478
Lymph node metastasis 0.76
  Positive2131
  Negative6362

[i] SLVI, skip lymphovascular invasion; CRC, colorectal carcinoma; Por, poorly differentiated adenocarcinoma; Muc, mucinous carcinoma; Well, well differentiated adenocarcinoma; Mod, Moderately poorly differentiated adenocarcinoma; Pap, papillary adenocarcinoma.

We also examined T1 and T2 CRCs together (Table III). Significant differences were observed concerning location (P<0.01) and lymphovascular invasion (P<0.01). There were no significant differences in other clinicopathological features. Table IV shows the details of T1 and T2 CRCs with SLVI. All cases showed lymphovascular invasion and were located in the sigmoid colon or rectum.

Table III.

Comparison of clinicopathological features between patients with and without skip lymphovascular invasion in T1 and T2 colorectal carcinomas.

Table III.

Comparison of clinicopathological features between patients with and without skip lymphovascular invasion in T1 and T2 colorectal carcinomas.

CharacteristicsWith SLVI (n=15)Without SLVI (n=1227)P-value
Sex 0.14
  Male11711
  Female4516
Age, years (range)64 (42–84)65 (25–94)0.96
Tumor size, mm (range)21 (10–37)25 (8–120)0.70
Location <0.01
  Sigmoid or rectum15857
  Other site0370
Lymphovascular invasion <0.01
  Positive15697
  Negative0530
Tumor differentiation 0.57
  Por or Muc019
  Well or Mod or Pap151,208
Lymph node metastasis 0.31
  Positive4213
  Negative111,014

[i] SLVI, skip lymphovascular invasion; CRC, colorectal carcinoma, Por, poorly differentiated adenocarcinoma; Muc, mucinous carcinoma; Well, well differentiated adenocarcinoma; Mod, Moderately poorly differentiated adenocarcinoma; Pap, papillary adenocarcinoma.

Table IV.

Details of the patients with SLVI in T1 and T2 colorectal carcinomas.

Table IV.

Details of the patients with SLVI in T1 and T2 colorectal carcinomas.

No.SexAgeTumor size (mm)LocationDepth of direct invasion (µm)Lympho-vascular invasionTumor differentiationMorphologyLNMRecurrence
  1F4233RT1 (3,800)+ModIIa+IIc
  2M7920ST1 (6,100)+WellIs
  3M7616ST1 (1,000)+WellLST-NG
  4M7822ST1 (6,750)+ModIs+IIc+
  5M6617ST1 (5,300)+WellIIa+IIc
  6M7013ST1 (5,900)+ModIIa+IIc+
  7F6216ST1 (3,800)+ModIIa+IIc
  8M5737RT2+WellType2
  9M6421ST2+ModType2Liver
10M5530ST2+WellType2
11M8420ST2+ModType2+
12M5927ST2+WellType2+Liver
13F6020RT2+ModType2
14M6620RT2+WellType2Liver, lung
15F4410ST2+ModType1

[i] SLVI, skip lymphovascular invasion; R, rectum; S, sigmoid colon; v, vascular invasion; ly, lymphatic invasion; Mod, moderately differentiated carcinoma; Well, well differentiated carcinoma; LST-NG; laterally spreading tumor-non granular; LNM, lymph node metastasis; F, female; M, male.

Discussion

In the present study, we retrospectively investigated the incidence and clinicopathological features of T1 and T2 CRCs with SLVI. The incidence of SLVI in T1 and T2 CRCs was 0.9 and 1.6%, respectively. All cases with SLVI were located in the sigmoid colon or rectum and showed lymphovascular invasion.

We focused on T1 CRCs with SLVI in the present study. With recent advances in endoscopic treatments, such as ESD, many T1 CRCs can be resected endoscopically with negative margin. Although endoscopic treatment is an attractive option for the patients, T1 CRCs show approximately 10% of LNM, which requires surgical colectomy with lymph node dissection to cure the cancer (1320). Therefore, it is important to reveal the risk factors for LNM in the patients with T1 CRCs, and we should decide whether additional surgery after endoscopic resection is needed according to the presence of risk factors for LNM. Previously identified risk factors for LNM in T1 CRCs are lymphovascular invasion, tumor budding, histological grade, and the degree of submucosal invasion. These risk factors are listed in current guidelines such as the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO) or JSCCR. Currently, these are the only indications for surgery after endoscopic resection in the patients with T1 CRCs (1,2124). However, a recent report has investigated T1 CRCs with SLVI (9). These lesions also need to undergo surgical resection because they have the potential to recur or to develop metastasis when treated with endoscopic resection alone. Specifically, we should decide the indication for surgery in patients with T1 CRCs in terms of not only the risk of LNM but also the existence of SLVI. We therefore planned this study, which investigated the risk factors for lesions with SLVI.

The incidence of T1 CRCs with SLVI was 0.9%, which were the same as previously reported (9). Our study revealed that lymphovascular invasion was a significant risk factor for SLVI in patients with T1 CRCs. Currently, the mechanism of SLVI remains unknown. All lesions with SLVI demonstrated lymphovascular invasion, and discontinuous foci were all lymphovascular invasion. Considering these results, lymphovascular invasion could be associated with the development of SLVI. There were no significant differences in other clinicopathological features. Thus, patients with T1 CRCs that show lymphovascular invasion are recommended for surgery after endoscopic resection. In addition, the JSCCR guidelines are appropriate regarding SLVI.

To reveal the features of CRCs with SLVI in more detail, we analyzed not only T1 CRCs but also T2 CRCs. The location, that is, the sigmoid colon or rectum, was a risk factor in T1 and T2 CRCs with SLVI accompanied by a significantly higher rate of lymphovascular invasion than CRCs without SLVI. This difference may have resulted from differences between anatomical features, such as blood vessel density, of the sigmoid colon/rectum and the other sites. Although all cases were located in the sigmoid colon or rectum, there were some cases with SLVI at locations other than the sigmoid colon or rectum in previous reports by Okamoto et al (9). Further research is needed.

There are some limitations to this study. First, this was a single center retrospective study. Although the sample size was larger than the previous report (9), there could be a regional or institutional selection bias. Second, we investigated only patients with surgically resected T1 CRCs because SLVI was not able to be diagnosed when treated by only endoscopic resection. Hence, the clinicopathological features identified in this study are not necessarily applicable to patients treated by endoscopic resection alone.

In conclusion, although the incidence is very low, there are some T1 CRCs with SLVI, and its risk factor is the presence of lymphovascular invasion. These lesions are likely to recur when treated by endoscopy alone. Therefore, T1 CRCs with lymphovascular invasion require surgical colectomy, which also follows the current JSCCR guidelines. To reveal the clinicopathological features of CRCs with SLVI in more detail, further research is needed.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Authors' contributions

YSa contributed to the study concept and drafted the manuscript. YSa and KI contributed to statistical analysis and interpretation of data. SK, FI and HM contributed to administrative support and study supervision. YSa, SK, KI, SM, YK, KK, TB, KW, TH, TK, NO, YM, MM, NT, TI, YY, HK, TS, YSh, KS, YK, SH, FI and HM contributed to data collection at Showa University and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T; Japan Cancer Surveillance Research Group, : Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 42:139–147. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Kobayashi N, Saito Y, Uraoka T, Matsuda T, Suzuki H and Fujii T: Treatment strategy for laterally spreading tumors in Japan: Before and after the introduction of endoscopic submucosal dissection. J Gastroenterol Hepatol. 24:1387–1392. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Oka S, Tanaka S, Saito Y, Iishi H, Kudo SE, Ikematsu H, Igarashi M, Saitoh Y, Inoue Y, Kobayashi K, et al: Local recurrence after endoscopic resection for large colorectal neoplasia: A multicenter prospective study in Japan. Am J Gastroenterol. 110:697–707. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Asayama N, Oka S, Tanaka S, Hayashi N, Arihiro K and Chayama K: Endoscopic submucosal dissection as total excisional biopsy for clinical T1 colorectal carcinoma. Digestion. 91:64–69. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Ozawa S, Tanaka S, Hayashi N, Nishiyama S, Terasaki M, Nakadoi K, Kanao H, Oka S, Yoshida S and Chayama K: Risk factors for vertical incomplete resection in endoscopic submucosal dissection as total excisional biopsy for submucosal invasive colorectal carcinoma. Int J Colorectal Dis. 28:1247–1256. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Hayashi T, Kudo SE, Miyachi H, Sakurai T, Ishigaki T, Yagawa Y, Toyoshima N, Mori Y, Misawa M, Kudo T, et al: Management and risk factor of stenosis after endoscopic submucosal dissection for colorectal neoplasms. Gastrointest Endosc. 86:358–369. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Gromski MA, Cohen J, Saito K, Gonzalez JM, Sawhney M, Kang C, Moore A and Matthes K: Learning colorectal endoscopic submucosal dissection: A prospective learning curve study using a novel ex vivo simulator. Surg Endosc. 31:4231–4237. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Okamoto Y, Mitomi H, Ichikawa K, Tomita S, Fujimori T and Igarashi Y: Study Group for Depth of Tumor Invasion projected by the Japanese Society for Cancer of the Colon and Rectum (JSCCR): Effect of skip lymphovascular invasion on hepatic metastasis in colorectal carcinomas. Int J Clin Oncol. 20:761–766. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Kudo S, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, et al: Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc. 68 4 Suppl:S3–S47. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Bosman FT, Carneiro F, Hruban RH and Theise ND: WHO Classification of Tumours of the Digestive System Lyon. France: 2010

12 

Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Miyachi H, Kudo SE, Ichimasa K, Hisayuki T, Oikawa H, Matsudaira S, Kouyama Y, Kimura YJ, Misawa M, Mori Y, et al: Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis. J Gastroenterol Hepatol. 31:1126–1132. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Ichimasa K, Kudo SE, Miyachi H, Kouyama Y, Hayashi T, Wakamura K, Hisayuki T, Kudo T, Misawa M, Mori Y, et al: Comparative clinicopathological characteristics of colon and rectal T1 carcinoma. Oncol Lett. 13:805–810. 2017. View Article : Google Scholar : PubMed/NCBI

15 

Bosch SL, Teerenstra S, de Wilt JH, Cunningham C and Nagtegaal ID: Predicting lymph node metastasis in pT1 colorectal cancer: A systematic review of risk factors providing rationale for therapy decisions. Endoscopy. 45:827–834. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Beaton C, Twine CP, Williams GL and Radcliffe AG: Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorectal Dis. 15:788–797. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Kimura YJ, Kudo SE, Miyachi H, Ichimasa K, Kouyama Y, Misawa M, Sato Y, Matsudaira S, Oikawa H, Hisayuki T, et al: ‘Head invasion’ is not a metastasis-free condition in pedunculated T1 colorectal carcinomas based on the precise histopathological assessment. Digestion. 94:166–175. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Kouyama Y, Kudo SE, Miyachi H, Ichimasa K, Hisayuki T, Oikawa H, Matsudaira S, Kimura YJ, Misawa M, Mori Y, et al: Practical problems of measuring depth of submucosal invasion in T1 colorectal carcinomas. Int J Colorectal Dis. 31:137–146. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Choi JY, Jung SA, Shim KN, Cho WY, Keum B, Byeon JS, Huh KC, Jang BI, Chang DK, Jung HY, et al: Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma. J Korean Med Sci. 30:398–406. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Ichimasa K, Kudo SE, Mori Y, Misawa M, Matsudaira S, Kouyama Y, Baba T, Hidaka E, Wakamura K, Hayashi T, et al: Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer. Endoscopy. 50:230–240. 2018.PubMed/NCBI

21 

Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A and Arnold D; ESMO Guidelines Working Group, : Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi64–vi72. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Glimelius B, Tiret E, Cervantes A and Arnold D: ESMO Guidelines Working Group: Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi81–vi88. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Rectal Cancer. (v.1.2017). 2017.

24 

Network NCC: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer. (v.1.2017). 2017.

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sato Y, Kudo SE, Ichimasa K, Matsudaira S, Kouyama Y, Kato K, Baba T, Wakamura K, Hayashi T, Kudo T, Kudo T, et al: Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion. Oncol Lett 16: 7264-7270, 2018
APA
Sato, Y., Kudo, S., Ichimasa, K., Matsudaira, S., Kouyama, Y., Kato, K. ... Miyachi, H. (2018). Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion. Oncology Letters, 16, 7264-7270. https://doi.org/10.3892/ol.2018.9527
MLA
Sato, Y., Kudo, S., Ichimasa, K., Matsudaira, S., Kouyama, Y., Kato, K., Baba, T., Wakamura, K., Hayashi, T., Kudo, T., Ogata, N., Mori, Y., Misawa, M., Toyoshima, N., Ishigaki, T., Yagawa, Y., Nakamura, H., Sakurai, T., Shakuo, Y., Suzuki, K., Kudo, Y., Hamatani, S., Ishida, F., Miyachi, H."Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion". Oncology Letters 16.6 (2018): 7264-7270.
Chicago
Sato, Y., Kudo, S., Ichimasa, K., Matsudaira, S., Kouyama, Y., Kato, K., Baba, T., Wakamura, K., Hayashi, T., Kudo, T., Ogata, N., Mori, Y., Misawa, M., Toyoshima, N., Ishigaki, T., Yagawa, Y., Nakamura, H., Sakurai, T., Shakuo, Y., Suzuki, K., Kudo, Y., Hamatani, S., Ishida, F., Miyachi, H."Clinicopathological features of T1 colorectal carcinomas with skip lymphovascular invasion". Oncology Letters 16, no. 6 (2018): 7264-7270. https://doi.org/10.3892/ol.2018.9527